Myriad Genetics Inc. (MYGN)

[surf1944]

7:08AM Myriad Genetics announces Myriad myRisk Hereditary Cancer test is 'highly accurate' in key validation study; five studies to be presented at the American Society of Human Genetics Annual Meeting (MYGN) 25.39 : Co announced it will present data this week at the American Society of Human Genetics (ASHG) annual meeting in Boston showing that the Myriad myRisk Hereditary Cancer test meets rigorous quality standards and provides clinical sequencing results equivalent to 99.99 percent accuracy. Myriad myRisk Hereditary Cancer is a new diagnostic test that provides patients with information about their hereditary risk for eight major cancers including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma. We've invested three years of research to optimize our Myriad myRisk Hereditary Cancer test, and the validation data show that Myriad myRisk Hereditary Cancer offers 99.99 specificity and sensitivity which means it provides unprecedented quality and accuracy equal to the gold standard Sanger sequencing."